Tactical Long on Exelixis: FDA Delay Is a Speed Bump, Not a Roadblock

Hook & thesis

Exelixis recently saw a knee-jerk reaction after a regulatory delay for a near-term filing. The market treated that delay like a binary negative, pushing shares down from their 52-week high of $59.72 to $56.12. My read: the market over-discounted Exelixis' franchise value. The company still earns roughly $3.47 in EPS and trades at a P/E near 16 as of 09/11/2026, with more than $1.17 billion in free cash flow on the balance sheet — metrics that support buying the dip.

This is a tactical, mid-term trade: the FDA delay is temporary; the underlying drivers — Cabometyx’s continuing revenue, an expanding pipeline (including recently approved zanzalintinib in certain indications), and a strong free cash flow profile — argue that the downside from a delay is limited. I recommend buying into weakness with a clearly defined stop and a reasonable upside target.

The business in plain terms and why it matters

Exelixis is a focused oncology company centered on cabozantinib (Cabometyx) and newer pipeline assets such as zanzalintinib. Cabometyx remains a commercial backbone while zanzalintinib and other pipeline programs supply growth optionality. Investors care because Exelixis combines a profitable commercial franchise with meaningful late-stage pipeline exposure — a rare mix among mid-cap oncology names.

Key fundamentals and what the numbers tell us (figures as of 09/11/2026)

Two quick takeaways from the numbers: first, valuation is reasonable for a cash-generating oncology name. A P/E around 16 and EV/EBITDA in the low-to-mid teens is not bubble territory for a company with positive operating leverage. Second, the balance sheet and cash flow profile matter here: Exelixis reports meaningful free cash flow ($1.17B) and essentially no net leverage in the headline debt/equity metric, giving the company optionality for buybacks, bolt-on R&D, or partnership investments.

Why the market overreacted

• Regulatory delays are binary events that attract headlines but rarely destroy underlying economics. A delay typically shifts the present value of future approvals, it does not eliminate them.
• Exelixis' core cash generator, Cabometyx, continues to contribute revenue and offset R&D spending while new approvals (zanzalintinib in select indications) de-risk parts of the pipeline.
• With a market cap near $13.9B and free cash flow of $1.17B, a single regulatory timing miss is unlikely to change solvency or the company’s ability to invest decisively in the pipeline.

Valuation framing

At $56.12 the company trades at ~16x trailing earnings (EPS $3.47) and roughly 13.3x EV/EBITDA. For an oncology company that remains cash flow positive and is adding potential new revenue streams from late-stage assets, those multiples are within a defensible range. The shares are only a few dollars below their 52-week high of $59.72, meaning this pullback is more volatility than permanent impairment.

Qualitatively, compare Exelixis to mid-cap oncology peers: many names trade at higher multiples with weaker cash flows or riskier pipelines. Exelixis' combination of an established commercial product and pipeline upside supports a valuation premium to speculative development-stage peers and a discount vs. large-cap integrated oncology majors — a middle ground that the market appears to be repricing too aggressively on the back of the delay.

Catalysts to watch (2-5)

• Regulatory updates and resubmission timelines for the delayed filing - an explicit timeline would remove uncertainty and is likely to re-rate the shares.
• Quarterly results showing continued Cabometyx revenue resilience and margin expansion; with strong free cash flow, the company can reinvest without a balance sheet strain.
• Clinical readouts or label expansions for zanzalintinib or other late-stage candidates that expand addressable markets beyond current approvals.
• Business development: partnerships or licensing deals that monetize non-core assets or accelerate commercialization in key regions.

Trade plan - actionable and time-boxed

My recommended trade: buy Exelixis at $56.12 with a stop at $50.00 and a target of $63.00. This is a mid-term tactical trade intended to play out over the next mid term (45 trading days). The thesis is that the regulatory calendar will firm up and investor attention will refocus on cash flow and pipeline milestones rather than timing risk alone.

Rationale for levels:

• Entry $56.12: current market price and near the recent pullback zone, providing reasonable reward-to-risk.
• Stop $50.00: a decisive move below $50 would signal broader sentiment shift and could indicate further downside to the prior consolidation band; this limits downside to roughly 10.9% from entry.
• Target $63.00: just above recent highs and reflects a recovery toward the prior trading range; reaching $63 implies ~12.3% upside from entry and allows capture of the likely short-covering and momentum re-acceleration if regulatory clarity returns.

Risks and counterarguments

• Regulatory risk persists: The most obvious risk is that the FDA delay is followed by further requests (additional trials or data), stretching timelines and reducing near-term probability of success. That outcome would pressure the stock materially.
• Commercial headwinds for Cabometyx: Cabometyx faces long-term generic competition (noted industry expectations point to generic pressure by early 2030), and any accelerating share loss would hurt near-term cash flow assumptions.
• Clinical disappointments elsewhere in the pipeline: Additional negative trial readouts or safety signals could undermine the broader growth story and investor appetite for Exelixis’ risk profile.
• High short interest can amplify volatility: While shorts can catalyze rallies if sentiment reverses, they can also extend selling pressure if negative headlines persist — be prepared for choppy price action and heavier intraday moves.

Counterargument: A reasonable opposing view is that the FDA delay is a symptom of deeper issues — for example, insufficient efficacy or unresolved safety concerns — which would meaningfully impair the pipeline’s value and force a lower multi-year revenue trajectory. If subsequent regulatory guidance requires large new trials or additional cohorts, the delay could indeed be more damaging than a timing issue. That scenario would likely push the fair value well below the current P/E multiple and justify a more conservative stance.

What would change my mind

I will reduce or exit the position if one of the following happens:

• Regulators explicitly require substantial new trials that push approval timelines beyond a reasonable commercial window.
• Quarterly results show a clear and accelerating decline in Cabometyx revenues or materially worse-than-guided margins.
• Multiple clinical failures in mid-to-late stage assets that remove the pipeline optionality supporting the current valuation.

Conclusion - clear stance

Buy the pullback in Exelixis with a mid-term time box. The FDA delay is unpleasant but, at current levels, does not materially impair the company’s cash generation or longer-term growth optionality. With free cash flow above $1 billion, minimal headline leverage, and a reasonable P/E, the stock offers an asymmetric trade: defined downside with a path to a high single-digit to low double-digit percentage gain if regulatory clarity and pipeline catalysts reappear. Execute the trade with the $56.12 entry, $50.00 stop, and $63.00 target, and monitor regulatory updates and quarterly results closely.